Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7655000 | 0.80 | HSD11B1 (0.36) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL1091053 | 0.78 | NOTUM (0.40) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL461807 | 0.78 | HSD11B1 (0.35) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL15110040 | 0.78 | HSD11B1 (0.35) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL443319 | 0.78 | HSD11B1 (0.38) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL23791454 | 0.78 | HSD11B1 (0.35) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL7602702 | 0.78 | KDM4E (0.35) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL10094578 | 0.77 | NPC1 (0.41) | HSD11B1GPR119MAOAMAOBMEN1 | |
| SCHEMBL15932001 | 0.75 | HSD11B1 (0.36) | HSD11B1GPR119MEN1KMT2A | |
| SCHEMBL10094574 | 0.75 | HSD11B1 (0.45) | HSD11B1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1756084-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121121-A2 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036434-A1 | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP11B1 | HSD11B1 108/4885GPR119 31/4885MAOA 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.